 Quality-Adjusted Life Years
"Quality-Adjusted Life Years" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A measurement index derived from a modification of standard life-table procedures and designed to take account of the quality as well as the duration of survival. This index can be used in assessing the outcome of health care procedures or services. (BIOETHICS Thesaurus, 1994)
| Descriptor ID |
D019057
|
| MeSH Number(s) |
E05.318.740.100.500.700 L01.280.975.475.700 N01.224.935.530.700
|
| Concept/Terms |
Quality-Adjusted Life Years- Quality-Adjusted Life Years
- Life Year, Quality-Adjusted
- Life Years, Quality-Adjusted
- Quality-Adjusted Life Year
- Year, Quality-Adjusted Life
- Years, Quality-Adjusted Life
- QALY
- Quality Adjusted Life Years
Adjusted Life Years- Adjusted Life Years
- Adjusted Life Year
- Life Year, Adjusted
- Life Years, Adjusted
- Year, Adjusted Life
- Years, Adjusted Life
|
Below are MeSH descriptors whose meaning is more general than "Quality-Adjusted Life Years".
Below are MeSH descriptors whose meaning is more specific than "Quality-Adjusted Life Years".
This graph shows the total number of publications written about "Quality-Adjusted Life Years" by people in this website by year, and whether "Quality-Adjusted Life Years" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 3 | 3 | | 1998 | 0 | 1 | 1 | | 1999 | 2 | 0 | 2 | | 2000 | 1 | 0 | 1 | | 2001 | 0 | 1 | 1 | | 2002 | 2 | 0 | 2 | | 2003 | 0 | 5 | 5 | | 2005 | 0 | 2 | 2 | | 2006 | 0 | 2 | 2 | | 2007 | 1 | 3 | 4 | | 2008 | 1 | 2 | 3 | | 2009 | 0 | 2 | 2 | | 2010 | 0 | 2 | 2 | | 2011 | 1 | 2 | 3 | | 2012 | 2 | 2 | 4 | | 2013 | 0 | 3 | 3 | | 2014 | 1 | 6 | 7 | | 2015 | 2 | 3 | 5 | | 2016 | 0 | 7 | 7 | | 2017 | 1 | 2 | 3 | | 2018 | 0 | 5 | 5 | | 2019 | 0 | 4 | 4 | | 2020 | 1 | 5 | 6 | | 2021 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Quality-Adjusted Life Years" by people in Profiles.
-
Mojtahed SA, Boyer NR, Rao SA, Gajewski TF, Tseng J, Turaga KK. Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare Patients. Ann Surg Oncol. 2021 Dec; 28(13):9039-9047.
-
Ackroyd SA, Huang ES, Kurnit KC, Lee NK. Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis. Gynecol Oncol. 2021 08; 162(2):249-255.
-
Shaffer SR, Huang E, Patel S, Rubin DT. Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis. Am J Gastroenterol. 2021 01 01; 116(1):125-133.
-
Noureddin M, Jones C, Alkhouri N, Gomez EV, Dieterich DT, Rinella ME. Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis. Gastroenterology. 2020 11; 159(5):1985-1987.e4.
-
Archer SL. Providing care for the 99.9% during the COVID-19 pandemic: How ethics, equity, epidemiology, and cost per QALY inform healthcare policy. Healthc Manage Forum. 2020 Sep; 33(5):239-242.
-
Dadwani RS, Skandari MR, GoodSmith MS, Phillips LS, Rhee MK, Laiteerapong N. Alternative type 2 diabetes screening tests may reduce the number of U.S. adults with undiagnosed diabetes. Diabet Med. 2020 11; 37(11):1935-1943.
-
Bhalla K, Gleason K. Effects of vehicle safety design on road traffic deaths, injuries, and public health burden in the Latin American region: a modelling study. Lancet Glob Health. 2020 06; 8(6):e819-e828.
-
Memeh K, Ruhle B, Vaghaiwalla T, Kaplan E, Keutgen X, Angelos P. Thyroidectomy for euthyroid patients with Hashimoto thyroiditis and persisting symptoms: A cost-effectiveness analysis. Surgery. 2021 Jan; 169(1):7-13.
-
Haddad R, Cohen EEW, Venkatachalam M, Young K, Singh P, Shaw JW, Korytowsky B, Abraham P, Harrington KJ. Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States. J Med Econ. 2020 May; 23(5):442-447.
-
GoodSmith MS, Skandari MR, Huang ES, Naylor RN. The Impact of Biomarker Screening and Cascade Genetic Testing on the Cost-Effectiveness of MODY Genetic Testing. Diabetes Care. 2019 12; 42(12):2247-2255.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|